Trial · NCT07895485
Ayres Sensory Integration Intervention for Children With Cerebral Palsy
NCT07895485, Not applicable, Not yet recruiting, Izgi Miray Demirbag
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ayres Sensory Integration Intervention for Children With Cerebral Palsy. Trials, record NCT07895485. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07895485
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ayres Sensory Integration Intervention for Children With Cerebral Palsy
- NCT number
- NCT07895485
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Izgi Miray Demirbag
- Conditions
- Cerebral Palsy (CP)
- Interventions
- Ayres Sensory Integration-Based Physiotherapy, Usual Physiotherapy and Rehabilitation
- First posted
- 2026-10-26
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Gross Motor Function Measure-88 | Baseline and Week 12 | Gross motor function will be assessed using the Gross Motor Function Measure-88 (GMFM-88). The GMFM-88 assesses lying and rolling, sitting, crawling and kneeling, standing, and walking, running, and jumping. The total score will be recorded at baseline and at the end of the 12-week study period. Change from baseline to Week 12 will be compared between groups. Higher scores indicate better performance. |
| Primary | Sensory Processing Measure | Baseline and Week 12 | Sensory processing will be assessed using the parent-report Sensory Processing Measure (SPM). Scores will be recorded at baseline and at the end of the 12-week study period. Change from baseline to Week 12 will be compared between groups. |
| Primary | Peabody Developmental Motor Scales, Second Edition | Baseline and Week 12 | Motor skills will be assessed using the Peabody Developmental Motor Scales, Second Edition (PDMS-2). Gross motor, fine motor, and total motor scores will be recorded at baseline and at the end of the 12-week study period. Changes from baseline to Week 12 will be compared between groups. Higher raw scores represent better performance. A Z-score between -1 and +1 indicates that the child's performance falls within the range expected for their age. Conversely, areas with a Z-score below -1 indicate that the child's performance is below what is expected for their age. |
| Primary | Pediatric Evaluation of Disability Inventory | Baseline and Week 12 | Functional skills will be assessed using the Pediatric Evaluation of Disability Inventory (PEDI), including self-care, mobility, and social function. Scores will be recorded at baseline and at the end of the 12-week study period. Change from baseline to Week 12 will be compared between groups. |
| Primary | Goal Attainment Scale | Goals established at baseline; goal attainment assessed at Week 12 | Individualized goals will be established in collaboration with the parents at the start of the intervention. Goal attainment will be assessed at the end of the 12-week study period using the Goal Attainment Scale. Each goal will be rated from -2 to +2, with 0 representing the expected level of attainment. The prespecified GAS score will be used for analysis. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07895485
GET https://conductscience.org/api/trials/v1/NCT07895485/registered